BRCA1 and ovarian carcinoma: In detail, the FDA accepted the clinical trials of rucaparib for BRCA1/2-mutated advanced ovarian carcinomas undergoing multiple chemotherapy treatments in 2016 [68], reoccurring ovarian, fallopian and primary peritoneal carcinoma without BRCA1/2 mutational status in 2018 [69] and BRCA1/2-mutated metastatic castration-resistant prostate cancer in 2020 [70].